nach oben

World Journal of Urology

Erschienen in:

02.08.2016 | Topic Paper

Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study—Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7

verfasst von: Tobias Nordström, Martin Eklund, Henrik Grönberg

Erschienen in: World Journal of Urology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Excerpt

The recent work of Grönberg et al. [1] may influence future guidelines on detection of prostate cancer. The report was published in a general oncology journal and is further commented below by the author group. …

Grönberg H, Adolfsson J, Aly M et al (2015) Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. doi:10.1016/S1470-2045(15)00361-7 PubMed

Welch HG, Gorski DH, Albertsen PC (2015) Trends in metastatic breast and prostate cancer-lessons in cancer dynamics. N Engl J Med 373:1685–1687. doi:10.1056/NEJMp1510443 CrossRefPubMed

Arnsrud Godtman R, Holmberg E, Lilja H et al (2014) Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol 68:354–360. doi:10.1016/j.eururo.2014.12.006 CrossRefPubMed

Nordström T, Aly M, Clements MS et al (2013) Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003–2011. Eur Urol 63:419–425. doi:10.1016/j.eururo.2012.10.001 CrossRefPubMed

Drazer MW, Huo D, Eggener SE (2015) National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 33:2416–2423. doi:10.1200/JCO.2015.61.6532 CrossRefPubMed

Rider JR, Sandin F, Andrén O et al (2013) Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 63:88–96. doi:10.1016/j.eururo.2012.08.001 CrossRefPubMed

Grönberg H, Adolfsson J, Aly M et al (2016) Abstract 86: the STHLM3 model improves prostate cancer testing in men 50–69 years—further health economic and clinic evaluation. Eur Urol Suppl 15:1–1167. doi:10.1016/S1569-9056(16)60088-X CrossRef

Titel: Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study—Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7
verfasst von: Tobias Nordström
Martin Eklund
Henrik Grönberg
Publikationsdatum: 02.08.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1907-2

Neu im Fachgebiet Urologie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

10.04.2024 | PSA-Screening | Nachrichten

Einladung zum PSA-Screening senkt die Krebssterblichkeit

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet

05.04.2024 | Benigne Prostatahyperplasie | Nachrichten

TURP hat Vorteile im Vergleich mit der Embolisation

weitere anzeigen

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Accuracy of preoperative multiparametric magnetic resonance imaging for prediction of unfavorable pathology in patients with localized prostate cancer undergoing radical prostatectomy

Can intraperitoneal bupivacaine decreases pain in patients undergoing laparoscopic live donor nephrectomy? A randomized control trial

SIU Newsletter - June 2017

Prostate cancer trends in Asia

Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report